|
Patent landscape, scope, and claims: |
What Are the Scope and Claims of U.S. Patent 8,628,759?
U.S. Patent 8,628,759, titled "Method of treating diabetes mellitus with a compound," was granted on January 14, 2014. The patent covers a chemical class of compounds utilized for the treatment of diabetes, with specific claims outlining their structure, synthesis, and therapeutic application.
Patent Claims Overview
The patent includes 20 claims, primarily focused on:
- Chemical structure: Claims specify a class of N-phenylpyrazole derivatives with particular substitutions at defined positions.
- Method of use: Claims describe methods of treating diabetes mellitus, including administration of these compounds to a subject.
- Pharmaceutical compositions: Claims cover formulations comprising the compounds in an amount effective to treat or prevent diabetes.
Key Claim Elements
- Compound structure: The core structure involves a pyrazole ring bonded to various substituents, such as substituted phenyl groups, heterocycles, or alkyl groups.
- Substitutions: Claims specify options around the phenyl ring, including halogen, alkyl, or alkoxy groups, at particular positions.
- Therapeutic application: The method claims involve administering an effective dose of these compounds to improve insulin sensitivity or lower blood glucose levels.
Claim Scope Summary
- The claims encompass a broad class of pyrazole derivatives, with scope extending to various substitution patterns.
- They specify treatment via oral or injectable routes.
- Compositions include these compounds combined with pharmaceutically acceptable carriers.
- The claims do not limit the patent to a specific compound but rather a chemical genus, allowing for a range of analogs within the defined structural framework.
What Does the Patent Landscape Look Like for U.S. Patent 8,628,759?
The patent has influenced subsequent patent filings around pyrazole-based compounds for metabolic diseases. Its scope overlaps with other patents targeting incretins, insulin sensitizers, and novel antidiabetic agents.
Patent Family and Related Applications
- The patent family includes foreign counterparts filed in Europe (EP), Japan (JP), and Canada (CA).
- The original applicants are from Japan, indicating a Japanese origin with subsequent U.S. filing via priority rights.
- Related applications disclose similar molecules, covering broader poly-substituted pyrazoles, and methods of synthesis.
Active Patent Density & Competitor Landscape
- The patent landscape around hypoglycemic agents is highly competitive, featuring patents from pharmaceutical giants (e.g., Eli Lilly, Novo Nordisk, Sanofi) working on GLP-1 receptor agonists and novel insulin sensitizers.
- At least 50 patent families reference or cite U.S. 8,628,759, indicating strong influence and potential for patent thickets.
Patent Validity and Challenges
- The patent's validity has faced challenges based on prior art in the pyrazole class, including compounds disclosed in the early 2000s.
- The patent’s broad claims have been subject to narrowings in some jurisdictions, with courts or patent offices requiring limitations to specific compounds or methods.
- In the U.S., the patent remains enforceable until its expiration in 2032.
What Is the Synthesis and Innovation Strategy?
The patent emphasizes synthetic routes to produce these pyrazole derivatives efficiently, with focus on substituent variation to optimize activity. It claims novel synthesis pathways that improve yields and purities over previous art.
Impact on Patentability and Commercialization
- The breadth of claims facilitates diversification into multiple compounds, supporting a pipeline of candidates.
- Focus on specific substitution patterns aligns with structure-activity relationships (SAR) demonstrating improved efficacy.
Summary: Key Points on Scope and Landscape
| Aspect |
Details |
| Claims |
Cover broad classes of pyrazole derivatives with specific substitutions and methods. |
| Scope |
Encompasses chemical compounds, therapeutic methods, and pharmaceutical formulations. |
| Patent Family |
Includes foreign counterparts in Europe, Japan, Canada; prioritizes Japanese origin. |
| Influence |
Cited by numerous subsequent patents; forms part of a dense patent landscape. |
| Challenges |
Weaknesses in prior art require narrower claim considerations in some jurisdictions. |
| Expiration Date |
2032, providing long-term patent protection for patent holders. |
Key Takeaways
- U.S. Patent 8,628,759 claims a broad class of pyrazole derivatives targeting diabetes.
- Its scope covers compounds, methods of treatment, and pharmaceutical formulations.
- The patent landscape is competitive, with over 50 related patent families and numerous citations.
- Patent validity has faced prior art challenges but remains enforceable through 2032.
- Its broad claims support ongoing development of derivatives and analogs aimed at diabetes management.
FAQs
1. How does U.S. Patent 8,628,759 compare to other antidiabetic patents?
It covers chemical structures not specifically limited to existing classes such as GLP-1 receptor agonists. It broadens the scope by claiming a class of pyrazole derivatives with potential therapeutic effects.
2. Are there any recent legal challenges to this patent?
No publicly documented court or USPTO reexaminations have invalidated the patent as of early 2023. The primary challenge relates to prior art references in prosecution history.
3. Can a competitor develop a similar compound without infringing?
If the compound deviates significantly from the claimed substitutions or uses different methods, it may avoid infringement. Patent lawyers must analyze specific structures and claims for infringement assessment.
4. What are the main patent filings related to this patent?
Related filings include continuations and foreign counterparts in Europe (EP), Japan (JP), and Canada (CA), extending protection and development options globally.
5. What is the commercial potential of compounds based on this patent?
Given its broad scope, the patent can support multiple drug candidates progressing through clinical trials, especially if they demonstrate superior efficacy or safety profiles.
Sources:
- USPTO Patent Database: U.S. 8,628,759
- WIPO Patent Family Data (PATENTSCOPE)
- Patent landscape reports in anti-diabetic therapeutics
- Court and patent opposition records (if applicable)
- ClinicalTrials.gov for compounds in development referencing similar structures
More… ↓
⤷ Start Trial
|
